Bristol-Myers Squibb stock (US1078421011): valuation metrics in focus after recent share price move

Bristol-Myers Squibb shares on the NYSE traded moderately higher on 06/05/2026, keeping the U.S. biopharma group in focus as investors weigh its earnings profile, dividend yield and valuation multiples against large-cap pharmaceutical peers.

Bristol-Myers Squibb shares were quoted higher on the New York Stock Exchange on 06/05/2026, with the stock opening at USD 56.71 according to MarketBeat data referencing NYSE trading as of that date, highlighting continued investor attention on the U.S. biopharma group’s valuation and income profile.

The company, headquartered in the United States and listed on the NYSE under the ticker BMY, remains a key constituent of the large-cap U.S. pharmaceuticals space as investors monitor its earnings power, cash flow generation and oncology pipeline.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bristol-Myers Squibb
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology, cardiovascular, immunology and hematology therapies
• Home exchange/listing venue: New York Stock Exchange (BMY)
• Trading currency: USD

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on researching, developing and commercializing prescription medicines for serious diseases, with revenue driven largely by oncology and immunology products alongside cardiovascular and hematology treatments.

Valuation metrics and multiples for Bristol-Myers Squibb

On 06/05/2026, MarketBeat reported that Bristol-Myers Squibb opened at USD 56.71 on the NYSE, implying a market capitalization of USD 115.81 billion and a price-to-earnings ratio of 17.02 for the company at that time, reflecting how the market values its current earnings base relative to other large pharmaceutical groups.MarketBeat as of 06/05/2026

The same MarketBeat overview dated 06/05/2026 noted that eight analysts rated the stock as Buy, ten as Hold and one as Sell, with a consensus target price of USD 61.31, offering a snapshot of how the sell-side community collectively prices Bristol-Myers Squibb’s earnings and pipeline prospects over the medium term.MarketBeat as of 06/05/2026

Conclusion

The latest NYSE quote and derived valuation metrics for Bristol-Myers Squibb on 06/05/2026 underline how the market currently prices the U.S. pharmaceutical group’s earnings stream and late-stage pipeline.

Combined with the spread of analyst recommendations and the consensus target price reported on the same date, investors gain additional context on how the stock is positioned within the broader large-cap biopharma universe without implying any specific trading stance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.